Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Panel Denies Members' Request To Investigate Provenge Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Bipartisan group looking to investigate conflict of interest at an FDA advisory committee on Provenge were stopped in their tracks by a letter from Energy & Commerce Committee leaders.

You may also be interested in...



Life Beyond Provenge: Dendreon Plans To Move First Small Molecule Into The Clinic

While Dendreon awaits data to complete the prostate cancer vaccine’s BLA, other candidates progress.

Life Beyond Provenge: Dendreon Plans To Move First Small Molecule Into The Clinic

While Dendreon awaits data to complete the prostate cancer vaccine’s BLA, other candidates progress.

Provenge Review In 2008 Hinges On IMPACT Interim Analysis

FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel